A recent study questions the reliability of molecular markers in immunotherapy responses. This finding paves the way for finding better alternatives within the scientific community. An FDA-approved genetic blood test may revolutionize cancer diagnosis by detecting gene changes linked to certain cancers. However, only 16% of US community cancer clinics provide mental health support to caregivers, highlighting a significant gap in patient care. For localized kidney cancer, Stereotactic Body Radiotherapy shows promise in improving patient outcome. A promising clinical trial illustrates that Atezolizumab could significantly enhance sarcoma treatment. At the same time, ENLACE is striving to rectify the underrepresentation of Hispanic/Latino communities in cancer research. Lastly, engineered viruses providing improved immunity and tumor reduction are a potentially advantageous approach in future cancer treatment.
Full article here: https://medium.com/@lawsuithelpdesk/immunotherapy-response-questioning-the-accuracy-of-molecular-markers-f5df1fa698b2
